Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Novartis announced that Rhapsido (remibrutinib) met primary endpoints in the Phase III RemIND trial across three chronic inducible urticaria subtypes, demonstrating twice the symptom control rate versus placebo. The company has submitted an FDA application for the symptomatic dermographism subtype, with additional global regulatory filings planned for 2026. This represents the first targeted therapy for CIndU, addressing an unmet medical need affecting 29 million patients worldwide.